Early access
Sign in
Taking peoplePhase 1

Tests oral MBQ-167 in people with advanced breast cancer

Tests a pill, MBQ-167, in adults with advanced breast cancer.

Key facts

Who runs it
MBQ Pharma
Where
San Juan, Puerto RicoSee the siteAlso in 1 other country, 3 sites
Trial code
Registry title
A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer
Status
Recruiting
Phase
Phase 1
People taking part
48 people, planned
Started
9 Nov 2023
Expected to end
31 Dec 2026
Type of study
Interventional
Treatments tested
  • MBQ-167
Record updated
31 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced breast cancer who have already tried approved treatments, or for whom no standard treatment is available.

Age
21 years or older
Sex
All sexes
Disease stage
Advanced breast cancer, confirmed by tissue or cell tests, that got worse after approved treatments or has no standard treatment
Earlier treatment
Must have had approved therapies that stopped working, or have no standard therapy available. No anticancer treatment within 4 weeks and no investigational agent within 28 days before the first dose.

Main reasons for not taking part

  • Cannot take oral medication, or has a stomach or bowel problem that could affect the drug
  • Pregnant or breastfeeding
  • Has not recovered from side effects of earlier cancer treatment (more than Grade 0 or 1)
  • Another active cancer besides advanced breast cancer
  • Cannot swallow capsules twice a day with a meal

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • The investigator will evaluate these and other criteria to determine whether a participant can be included in this study
  • Histologically and/or cytologically confirmed advanced breast cancer which has progressed after treatment with approved therapies or for which there are no standard therapies available
  • Participants with known brain metastases may be eligible if specific conditions are met
  • Life expectancy ≥6 months, in the opinion of the investigator, after starting MBQ-167
  • Are able to swallow capsules twice daily with a meal

Who cannot take part

  • Participants who have received any anticancer treatment within 4 weeks or any investigational agent within 28 days prior to the first dose of trial drug or who have not recovered from any acute toxicity greater than Grade 0 or 1 related to previous anticancer treatment
  • Participants who have received any anticancer treatment within 4 weeks or any investigational agent within 28 days prior to the first dose of trial drug or who have not recovered from any acute toxicity greater than Grade 0 or 1 related to previous anticancer treatment
  • Inability to take oral medication, or malabsorption syndrome or any other uncontrolled gastrointestinal condition (e.g., nausea, diarrhea, or vomiting) that might impair the bioavailability of MBQ-167
  • Active malignancies other than advanced breast cancer will be excluded from the study
  • The investigator will evaluate these and other criteria to determine whether a participant should be excluded from this study
  • Females who are pregnant or breastfeeding

Where in Puerto Rico

Also in 1 other country, 3 sites

  • FDI Clinical ResearchSan Juan, Puerto RicoContact: Scott HoustonNo longer taking part

About the trial

What the trial wants to find out

A Phase 1, open-label, dose-escalation clinical trial of MBQ-167 in participants with advanced Breast Cancer for whom Standard of Care (SOC) has failed or has proven intolerable.

The group in the trial

  • MBQ-167 oral capsuleTreatment being tested

    A dose ranging from 10mg to 400mg BID following a standard 3+3 cohort design

    Treatment: MBQ-167

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase 1 Open-Label, First-in-Human Trial of Oral MBQ-167 as Single Agent in Participants With Advanced Breast Cancer
Plain-language title
Tests oral MBQ-167 in people with advanced breast cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
31 August 2026